E

Evolution Research Group | Woodland Research Northwest

Research site

(Unclaimed)

Location

609 W Dyke Road, Rogers, Arkansas, United States of America

Site insights

Top conditions

Top treatments

SEP-363856

Rapastinel

Edaravone

Cariprazine

Brexpiprazole

MK-8189

Risperidone

JNJ-42847922

Glucose

Rimegepant

Parent organization

This site is a part of Evolution Research Group

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 60 total trials

A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease

This is a 17-week double-blind, placebo-controlled, randomized, flexible-dosing, parallel-group, multicenter study designed to evaluate the efficacy...

Enrolling

Tremor

Parkinson Disease

Drug: Suvecaltamide

Drug: Placebo

BPL-003 Efficacy and Safety in Treatment Resistant Depression

This is a Phase 2 study randomized, quadruple masked, multi-center study designed to investigate the efficacy and safety of a single dose of BPL-003...

Enrolling

Treatment Resistant Depression

Drug: BPL-003

Changes in Biomarker of Exposure in Adults Who Smoke Cigarettes Switching From Cigarettes to Heated Tobacco Products

The purpose of the study is to evaluate changes in biomarkers of exposure (BoE) to harmful and potentially harmful constituents (HPHCs) in adult smok...

Active, not recruiting

Tobacco Use

Other: Smoking Abstinence (menthol)

Other: Smoking Abstinence (non-menthol)

ENCALM: a Study of ENX-102 As a Monotherapy Treatment in Patients with Generalized Anxiety Disorder

The ENCALM trial is designed to evaluate the efficacy and safety of ENX-102 in patients diagnosed with generalized anxiety disorder (GAD)

Enrolling

Generalized Anxiety Disorder

Drug: Placebo

Drug: ENX-102

Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia

This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center inpatient study to evaluate the efficacy and safety of LB-102 in adult...

Active, not recruiting

Schizophrenia

Drug: LB-102